

INDEX

A

Abdomen
in actinomycosis, Nov. 65
infection, Nov. 4-18
cephalosporins in, July 47-48
postoperative, Nov. 7-8
therapy, Nov. 16-18
of wall, Nov. 8
wound infections, Nov. 7-8
paracentesis, ascitic fluid during,
Sept. 34

Abortion: septic, Nov. 25-26

Abscess
brain (*see* Brain abscess)
epidural, Oct. 48
gas, Nov. 43-44
intraperitoneal, Nov. 8-9
liver, Nov. 14-15
muscle, Nov. 55
peritonissilar, Oct. 55-56
retroperitoneal, Nov. 18-19
skin, Nov. 37-39
anaerobes in, incidence of,
Nov. 38
subcutaneous, Nov. 37-39
anaerobes in, incidence of,
Nov. 38
subphrenic, Nov. 8-9

Achilles tendon: necrosis of, Nov.
33

Acidosis: D-lactic, Nov. 76

Acromegaly: and sleep apnea
syndrome, May 45-46

Actinomycosis, Nov. 64-68
abdominal form, Nov. 65
cervicofacial form, Nov. 64-65
diagnosis, Nov. 66-67
therapy, Nov. 67-68
thoracic form, Nov. 65

Adrenal: anorexia nervosa, June
22

Age: in coronary artery disease,
Dec. 20

Aged: drugs causing confusion in,
Apr. 53

Airway
abnormalities, anatomical, May
47-48
challenges, lung host defenses
for, Feb. 8-9
conducting, and host defense,
Feb. 18-19
normal, microbial flora of, Feb.
19-21
pharyngeal, in sleep apnea, May
11

Allergic reactions: to
cephalosporins, July
50-51

Alveolar
macrophage
chemotactic factors produced
by, Feb. 63-66
culture supernates, pooled, gel
filtration of, Feb. 64
defects contributing to
pneumonia, Feb. 66-78
interplay with
polymorphonuclear
granulocytes, Feb. 60-63
spaces, host defenses of, Feb.
55-81

Alzheimer's disease, Apr. 8-69
(*See also* Dementia syndrome)
basic mechanisms in, Apr.
35-37

behavioral support, Apr. 61
brain function in, Apr. 34
caring for patients with, Apr.
56-65

cell loss in, Apr. 28-29
cellular mechanisms in, Apr.
34-35

INDEX

A

Abdomen
in actinomycosis, Nov. 65
infection, Nov. 4-18
cephalosporins in, July 47-48
postoperative, Nov. 7-8
therapy, Nov. 16-18
of wall, Nov. 8
wound infections, Nov. 7-8
paracentesis, ascitic fluid during,
Sept. 34

Abortion: septic, Nov. 25-26

Abscess
brain (*see* Brain abscess)
epidural, Oct. 48
gas, Nov. 43-44
intraperitoneal, Nov. 8-9
liver, Nov. 14-15
muscle, Nov. 55
peritonissilar, Oct. 55-56
retroperitoneal, Nov. 18-19
skin, Nov. 37-39
anaerobes in, incidence of,
Nov. 38
subcutaneous, Nov. 37-39
anaerobes in, incidence of,
Nov. 38
subphrenic, Nov. 8-9

Achilles tendon: necrosis of, Nov.
33

Acidosis: D-lactic, Nov. 76

Acromegaly: and sleep apnea
syndrome, May 45-46

Actinomycosis, Nov. 64-68
abdominal form, Nov. 65
cervicofacial form, Nov. 64-65
diagnosis, Nov. 66-67
therapy, Nov. 67-68
thoracic form, Nov. 65

Adrenal: anorexia nervosa, June
22

Age: in coronary artery disease,
Dec. 20

Aged: drugs causing confusion in,
Apr. 53

Airway
abnormalities, anatomical, May
47-48
challenges, lung host defenses
for, Feb. 8-9
conducting, and host defense,
Feb. 18-19
normal, microbial flora of, Feb.
19-21
pharyngeal, in sleep apnea, May
11

Allergic reactions: to
cephalosporins, July
50-51

Alveolar
macrophage
chemotactic factors produced
by, Feb. 63-66
culture supernates, pooled, gel
filtration of, Feb. 64
defects contributing to
pneumonia, Feb. 66-78
interplay with
polymorphonuclear
granulocytes, Feb. 60-63
spaces, host defenses of, Feb.
55-81

Alzheimer's disease, Apr. 8-69
(*See also* Dementia syndrome)
basic mechanisms in, Apr.
35-37

behavioral support, Apr. 61
brain function in, Apr. 34
caring for patients with, Apr.
56-65

cell loss in, Apr. 28-29
cellular mechanisms in, Apr.
34-35

chemical characteristics, Apr. 31-33
consensus criteria, Apr. 42-43, 44-45
definition, Apr. 10-14
changes in terminology, Apr. 12-13
current usage, Apr. 13-14
original description, Apr. 10-12
diagnosis, differential, Apr. 42-54
earliest manifestations, Apr. 18-19
electron microscopic studies in, Apr. 30-31
epidemiology, Apr. 14-17
ethical concerns, Apr. 64-65
evaluation, clinical, Apr. 54-56
gross manifestations, Apr. 25
hospitalization in, Apr. 62
lesions of, characteristic, Apr. 25-28
medical care of, Apr. 56-57
natural history, Apr. 17-24
neurofibrillary tangles in, Apr. 27
pathology, Apr. 24-33
pathophysiology, Apr. 34-37
progression rate, Apr. 23-24
psychotropic medication in, Apr. 57-60
risk factors for, Apr. 15-17
social support in, Apr. 62-64
stages
late, Apr. 22-23
middle, Apr. 19-21
structural damage in, Apr. 34
subcortical nuclei in, Apr. 29-30

Amdinocillin, July 41
Amnionitis, Nov. 27
Amoxicillin: in anaerobic infection, Oct. 29, 31
Ampicillin: in anaerobic infection, Oct. 29, 31
Amyotrophic lateral sclerosis:
possible viral etiology, Aug. 67-68

Anaerobes
beta-lactamase-producing, Oct. 31
incidence as normal flora, Oct. 21
susceptibility to antimicrobial agents, Oct. 30
in urine, voided, Nov. 28-30

Anaerobic bacteria: isolated from blood, distribution of clinically significant, Oct. 39

Anaerobic culture, Oct. 23-25
specimen collection, Oct. 23-25
recommended methods for, Oct. 24
specimen transport, Oct. 25

Anaerobic infection, Oct. 8-77, Nov. 4-97
amoxicillin in, Oct. 29, 31
ampicillin in, Oct. 29, 31
antimicrobial therapy, Oct. 28
azlocillin in, Oct. 31
beta-lactamase inhibitors in, Oct. 35-36
carbenicillin in, Oct. 31
cefoxitin in, Oct. 31-32
cephalosporins in, Oct. 31-32
in children, Nov. 88-90
chloramphenicol in, Oct. 35
clindamycin in, Oct. 34
clues to, clinical, Oct. 26
dosage of drugs in, initial, Oct. 38
doxycycline in, Oct. 34
erythromycin in, Oct. 32
general features, Oct. 25-26
historical aspects, Oct. 8-11
host factors that may predispose to development of, Oct. 21
incidence
of anaerobes in infection, Oct. 17
of specific anaerobes in various infections, Oct. 19-20
infections commonly involving anaerobes, Oct. 15-16
management, Oct. 27-38
medical therapy, Oct. 28-38

Anaerobic infection (cont.)
 methicillin in, Oct. 31
 metronidazole in, Oct. 35
 mezlocillin in, Oct. 31
 minocycline in, Oct. 34
 nafcillin in, Oct. 31
 normal flora, Oct. 11-16
 incidence of various anaerobes
 as, Oct. 21
 pathogenesis, Oct. 17-23
 penicillin in, asoxazolyl, Oct. 31
 penicillin G in, Oct. 29
 penicillin V in, Oct. 29, 31
 piperacillin in, Oct. 31
 side effects of drugs for, Oct. 33
 surgical therapy, Oct. 27
 susceptibility testing and, Oct. 28
 taxonomy, Oct. 10-11
 tetracycline in, Oct. 32, 34
 ticarcillin in, Oct. 31
 toxicity of drugs for, Oct. 33
Anaerobic pathogens
 common, Oct. 10
 important, Oct. 10
Androgen: excess and sleep apnea syndrome, May 46-47
Angina
 in men (see *Electrocardiography, exercise, in men with angina*)
 pain of, classification rule for, Dec. 22
 Vincent's, Oct. 55-56
 in women (see
 Electrocardiography, exercise, in women, with angina)
Ankylosing (see *Spondylitis, ankylosing*)
Anorexia nervosa, June, 9-34
 adrenal in, June 22
 behavior modification in, June 32
 biologic considerations, June 12-13
 body image disturbance in, June 16-17
cardiovascular system in, June 23
cognitive deficits in, June 17-18
diagnosis, June 25-27
diagnostic evaluation for other medical disorders, June 27
endocrine dysfunction in, June 18-23
epidemiologic features, June 10-12
family therapy in, June 33
gastrointestinal system in, June 24
gonadal dysfunction in, June 18-21
growth hormone in, June 22-23
hematologic abnormalities in, June 24
ineffectiveness in, sense of, June 17
insight-oriented therapy of, June 32
management, nutritional/medical, June 29-32
medical features, June 18-25
nutrition in, measurements, June 24-25
outcome, June 33-35
patient with anorexia nervosa, June 15-18
perceptual disturbances in, June 17
pharmacotherapy of, June 32
premorbid psychosocial features, June 13-15
prognosis, June 33-35
prognostic factors in, long-term, June 35
Prognostic Nutritional Index, June 28
psychotherapy of, June 32-33
thyroid in, June 21
treatment, June 27-29
vasopressin in, June 23
weight gain after therapy in, June 34
Antabuse reaction, July 16

Antianginal drugs: starting in coronary artery disease, Dec. 33

Antibiotic(s) penetration into body fluids, July 25 in peritonitis, bacterial, Sept. 36-39

Antibodies: in chronic virus infection, Aug. 17-18

Antigens: viral, changes in, Aug. 15-16

Antimicrobial agents in anaerobic infection, Oct. 28 in colitis, pseudomembranous, Nov. 70-72 comparison of, Oct. 37 in diarrhea, Nov. 70-72 investigational, July 38-43 microbial susceptibility to, July 39 synopsis, July 42-43 susceptibility of anaerobes to, Oct. 30

Apnea (*see* Sleep, apnea)

Appendiceal infections, Nov. 10-11

Appliances: in sleep apnea syndrome, May 21

Arrhythmia with dual-chamber pacing, Mar. 31-37 initiated by dual-chamber pacemaker, Mar. 31-33 pacemakers and, Mar. 29-37 sustained by dual-chamber pacing, Mar. 33-36 with VVI pacemakers, Mar. 30-31

Arteries (*see* Coronary artery)

Arteriography: coronary, in coronary artery disease, Dec. 21

Arthritis mutilans, Jan. 33 psoriatic, Jan. 39-42 eight types, Jan. 39 reactive, features of, Jan. 36-37

rheumatoid, contrasted with enthesopathies, Jan. 11 spondylarthritis, seronegative, Jan. 10-17

Arthropathy: reactive, pattern of disease response, Jan. 15-17

Ascites bacterascites, Sept. 7-8 fluid during abdominal paracentesis, Sept. 34 analysis in spontaneous bacterial peritonitis, Sept. 14, 19-21 protein concentration in, Sept. 18 neutrocytic, culture-negative, Sept. 8-9 predisposing to infection, characteristics of, Sept. 28-33

Atrial activity, ventricular pacing synchronized to, Mar. 21 pacing, Mar. 38-39 hemodynamic comparison with ventricular pacing, Mar. 28 refractory period, treatment of pacemaker-mediated tachycardia by, Mar. 35 ventriculoatrial conduction and pacemaker syndrome, Mar. 27-29

Atrioventricular (*see* AV)

Autonomic dysfunction: and sleep apnea syndrome, May 42

AV block etiology, Mar. 8-10 pacing in, permanent, Mar. 8-12 pacing in, permanent, indications, Mar. 10-12 intervals and pacemakers, Mar. 46-47 sequential pacing, Mar. 21-24 synchrony restoration with DDD pacing, Mar. 29

AV (cont.)

- universal pacing, Mar. 24-26
- Azlocillin: in anaerobic infection, Oct. 31
- Aztreonam, July 38-40
- structure, July 40

B

- Back pain (see Pain, back)
- Bacterascites, Sept. 7-8
- Bacteremia, Oct. 38-42
 - anaerobic, portals of entry, Oct. 41
 - spontaneous, Sept. 7
 - urinary tract related, Nov. 30-31
- Bacteria
 - adherence to respiratory tract mucosa, and colonization, Feb. 21-23
 - anaerobic, isolated from blood, distribution of clinically significant, Oct. 39
 - inhaled into lungs, clearance of, factors responsible for, Feb. 13
 - systemic clearance, and intrahepatic shunting, Sept. 26-28
- Bacterial peritonitis (see Peritonitis, bacterial)
- Bacterial synergistic gangrene, Nov. 44-45
- "Bamboo" spine: in spondylitis, Jan. 14
- Bayes' theorem, Dec. 9-10
- Behavior modification: in anorexia nervosa, June 32
- Behavioral scale: for dementia, Apr. 41
- Beta-lactamase
 - cephalosporin and, July 11
 - inhibitors in anaerobic infection, Oct. 35-36
 - producing anaerobes, Oct. 31
- Bifascicular block: chronic, permanent pacing in, indications, Mar. 14

Biliary tract infections, Nov. 12-14

- Bite wound infections, Nov. 42-43

Block

- AV (see AV, block)
- bifascicular, chronic, permanent pacing in, indications, Mar. 14
- trifascicular, chronic, permanent pacing in, indications, Mar. 14

"Blue blasters:" vs. "pink puffers," May 37-41

- Body image: disturbances in anorexia nervosa, June 16-17

Bone

- infection, Nov. 57-61
 - cephalosporins in, July 48-49
- involved in osteomyelitis, anaerobic, Nov. 59

- Botulism, Nov. 77-82
 - clinical picture, Nov. 79-80
 - diagnosis, Nov. 80-81
 - epidemiology, Nov. 78-79
 - pathogenesis, Nov. 79
 - therapy, Nov. 81-82

- Bowel
 - bacterial overgrowth syndromes, Nov. 74-76
 - hyperplasia, lymphonodular, with immunoglobulin A deficiency, Nov. 76
 - inflammatory bowel disease, Jan. 43-44
 - management, Jan. 44

- Bradyarrhythmias: pacing in, indications, Mar. 8-18
- Brain abscess, Oct. 44-49
 - clinical features, Oct. 45-46
 - diagnostic evaluation, Oct. 46-47

- etiology agents, Oct. 45
- pathogenesis, Oct. 44-45
- therapy, Oct. 47-48

- Brain: function in Alzheimer's disease, Apr. 34

- Breast infection, Nov. 32-33

Breathing
in asymptomatic subjects, May 25-30
epidemiology, May 25-27
during sleep, baseline changes, May 30-31
Bronchitis: chronic, and secretory IgA, Feb. 23-28
Bulimia, June 35-45
binge-purge cycle in, June 38-39
development of coping strategies, June 43
diagnosis, June 41
epidemiologic features, June 36-38
medical features, June 40
outcome, June 44-45
pathogenesis, June 39-40
patient with bulimia, June 37-38
pharmacotherapy, June 43-44
premorbid features, June 37
prognosis, June 44-45
psychosocial features, June 36-38
psychotherapy in, June 42-43
self-monitoring in, June 43-43
treatment, June 41-45
Burn wound infections, Nov. 47
Bursa: subacromial, pus from, Nov. 33
Buttock: infections of, Nov. 32
Bypass
enteropathy, Nov. 75
gastric, illustration, May 19
ideal, for obesity, Nov. 75

C

Calcification
at enthesis in ankylosing spondylitis, Jan. 9
in spondylitis, advanced, Jan. 14
Cancrum oris, Nov. 46
Carbenicillin
in anaerobic infection, Oct. 31
structure, July 14
Cardiac (see Heart)

Cardiovascular system: in anorexia nervosa, June 23
Care: and Alzheimer's disease, Apr. 56-65
Cefoperazone: structure, July 15
Cefoxitin, July 32-34
in anaerobic infection, Oct. 31-32
clinical correlates, July 33-34
structure, July 17
Ceftazidime, July 38
Cefuroxime: structure, July 14
Cell(s)
-associated viral infections, Aug. 16-17
loss in Alzheimer's disease, Apr. 28-29
-mediated immunity, macrophages lacking, Feb. 75-78
membranes, failure of virus to express viral antigens on, Aug. 16
respiratory, forming rosettes with IgG subclass-erythrocyte complexes, Feb. 42
Cellulitis, Nov. 35
anaerobic, Nov. 43-44
clostridial, Nov. 43-44
orbital, Oct. 52-53
Central nervous system infections, Oct. 44-49
viral (see Virus infections, of central nervous system)
Cephalosporins, July 7-60
in abdominal infection, July 47-48
action mechanism, July 9-12
activity against *Pseudomonas*, July 35-38
clinical correlates, July 35-38
administration, July 17-23
adverse effects, July 50-52
allergic reactions to, July 50-51
in anaerobic infection, Oct. 31-32
available in 1985, July 10
in bone infections, July 48-49

Cephalosporins (cont.)
cost, July 36-37, 53-54
desacetylation reaction, July 28
disulfiram reaction, July 16
efficacy, July 52-53
elimination, July 27-28
ethyl alcohol metabolism and,
July 16
generations
definition of, July 28-38
first-generation, July 29-31
first-generation, clinical
correlates, July 31
second-generation, July 31-32
third-generation, July 34
glossary for, July 7-8
for granulocytopenic patient,
febrile, July 49
half-life, July 8
trends in, July 19
in joint infections, July 48-49
marketed in U.S., July 9
MBC, July 8
in meningitis, July 46-47
MIC, July 8
microbes susceptible to, July
26-27
nucleus of, July 12-16
oral
cost, July 37
pharmacokinetics, July 18
parenteral
cost, July 36
pharmacokinetics, July 20-21
penetration into body fluids,
July 24-27
pharmacokinetics, July 17-28
in pneumonia, July 44-46
protein binding, July 23-24
in renal failure, dosing interval,
July 23
R-1 side chains, July 7
R1 substituent, July 13
R-2 side chains, July 8
R2 substituent, July 14-16
safety, July 53
selection criteria for, July 52-54
in skin infections, July 48
in soft tissue infections, July 48
structure, July 13
structure-function relationships,
July 12-17
for surgical prophylaxis, July
49-50
therapeutic uses, July 43-50
toxic reactions to, July 51-52
in urinary tract infections, July
46

Cephamycins, July 16-17
Chemotactic factors: produced by
alveolar macrophages, Feb.
63-66

Chest
in actinomycosis, Nov. 65
expansion in ankylosing
spondylitis, Jan. 24-25
pain (see Pain, chest)

Children: anaerobic infections of,
Nov. 88-90

Chloramphenicol: in anaerobic
infection, Oct. 35

Cholangitis: acute ascending, Nov.
13-14

Cholecystitis: acute, Nov. 12-13

Ciliary
clearance, Feb. 28-34
defect, case review, Feb. 49-52
dysfunction, Feb. 29-34

Ciliotoxic infections, Feb. 32-34

Cilium: cross section of, Feb. 29

Clavulanate, July 41-42

Clavulanic acid: structure, July 42

Clindamycin: in anaerobic
infection, Oct. 34

Clostridial
cellulitis, Nov. 43-44
enteric diseases, Nov. 68-74
fasciitis, Nov. 50
food poisoning, Nov. 69
myonecrosis, Nov. 50-53

CNS (see Central nervous system)

Cognitive deficits: in anorexia
nervosa, June 17-18

Cognitive impairment: global, in
dementia syndrome, Apr.
39-42

Colitis: pseudomembranous, antimicrobial agents in, Nov. 70-72

Complement-mediated clearance: of microbes from lower respiratory tract, Feb. 73-74

Confusion: drugs causing, in aged, Apr. 53

Conjunctivitis, Oct. 50-51

Cordotomy: and sleep apnea syndrome, May 43

Cornea: infections of, Oct. 51

Coronary arteriography: in coronary artery disease, Dec. 21

Coronary artery disease, Dec. 7-71

- antianginal medication in, starting, Dec. 33
- complication rates of detection and treatment, Dec. 51-52
- counsel in, Dec. 33
- detection, complication rates of, Dec. 51-52
- diagnostic tests
 - effect on patient management, Dec. 33-34
 - results, useful, Dec. 33-34
- exercise predictors, Dec. 47
- exercise testing in, Dec. 7-71
- pretest risk, estimation of, Dec. 17-23
- exercise testing in prediction of, Dec. 52-54
- prevalence, Dec. 18
- estimation, clinical prediction rule for, Dec. 21
- probability, Dec. 34
- prognosis, Dec. 44-48
- prognostication, Dec. 33
- reassurance in, Dec. 33
- risk in asymptomatic persons, Dec. 50-51
- screening, Dec. 49-57
 - cost-effectiveness of, Dec. 56
 - effect of cardiac risk factors on yield of, Dec. 54-56
- effect of prior screening tests, Dec. 56
- exercise ECG for, Dec. 53
- rationale for, Dec. 49-50

severity

- chest pain, age and gender in, Dec. 20
- relationship with survival predictors, Dec. 47-48

ST-segment response to exercise as predictor of, Dec. 32

survival predictors, relationship with coronary artery disease severity, Dec. 47-48

treatment

- complication rates of, Dec. 51-52
- effect of, in asymptomatic persons, Dec. 51
- effect on outcome, Dec. 23-26

Coronary artery stenosis, left main detection of, Dec. 58-64

- by exercise tests, Dec. 59-62
- rationale for, Dec. 58
- exercise test prediction of, Dec. 61-62

myocardial scintiscan in, Dec. 61

pretest risk, estimation of, Dec. 58-59

Cost

- of coronary artery disease screening, Dec. 56
- of exercise ECG, Dec. 13
- of myocardial scintigraphy, stress thallium 201, Dec. 14

Counsel: in coronary artery disease, Dec. 33

Creutzfeldt-Jakob disease, Aug. 52-58

- clinical disease, Aug. 54-56
- diagnosis, Aug. 57-58
- epidemiology, Aug. 52-54
- laboratory findings, Aug. 56
- pathology, Aug. 56-57
- precautions in care of patients, Aug. 65-66

prognosis, Aug. 65

subtypes, clinical, Aug. 55-56

Creutzfeldt-Jakob disease (*cont.*)
 treatment, Aug. 65

Culture (*see* Anaerobic culture)

Cutaneous (*see* Skin)

Cyst

 inclusion, infected, Nov. 36
 pilonidal sinus, infected, Nov.
 46-47

 sebaceous, infected, Nov. 36

Cystic fibrosis, Feb. 34-38

 case review, Feb. 45-49

D

Death: sudden infant death
 syndrome and sleep apnea,
 May 50-52

Decubitus ulcer: infected, Nov.
 41-42

Dementia

 behavioral scale for, Apr. 41

 "the bits" causing, Apr. 53-54

 depression and, Apr. 48-49

 evaluation for, Apr. 46

 ischemic score and, modified,
 Apr. 47

 mixed, Apr. 48

 presenile, possible viral etiology,
 Aug. 68

 stroke causing, Apr. 43-47

 syndrome

 (*See also* Alzheimer's disease)

 degenerative diseases causing,
 Apr. 49-50

 diagnosis, Apr. 37-42

 diseases causing, Apr. 51

 epidemiology, Apr. 14-15

 global cognitive impairment

 in, Apr. 39-42

 impairment duration, Apr. 38

 mental status tests and, Apr.
 40

 sensorium and, clear, Apr. 38

 systemic illnesses causing, Apr.
 50-52

 toxic drug reactions and, Apr.
 52-53

Dental infections, Oct. 57-59

Depression: and dementia, Apr.
 48-49

Desacetylation reaction, July 28

Desaturation (*see* Oxygen,
 desaturation)

Diabetes mellitus: fetid foot of,
 Nov. 39-41

Diarrhea: antimicrobial agents in,
 Nov. 70-72

Disulfiram reaction, July 16

Diverticulitis, Nov. 11-12

D-lactic acidosis, Nov. 76

Doxycycline: in anaerobic
 infection, Oct. 34

Drug(s)

 in anaerobic infection

 side effects of, Oct. 33

 toxicity of, Oct. 33

 antiangina, starting in coronary
 artery disease, Dec. 33

 antimicrobial (*see* Antimicrobial
 agents)

 confusion in aged due to, Apr. 53
 in lung disease, chronic

 obstructive, May 40-41

 metabolizing, Nov. 77

 psychotropic, in Alzheimer's
 disease, Apr. 57-60

 in sleep apnea, May 19-21

 toxic reactions causing dementia
 syndrome, Apr. 52-53

Duodenum: infections related to,
 Nov. 16

Dystrophy: myotonic, and sleep
 apnea syndrome, May 43

E

Echovirus (*see*

 Meningoencephalitis,
 Echovirus)

Elderly: drugs causing confusion
 in, Apr. 53

Electrocardiography

 exercise, Dec. 10-13

 for coronary artery disease
 screening, Dec. 53

 in coronary artery stenosis,
 left main, Dec. 59-60

cost of, Dec. 13
 error in, sources of, Dec. 12
 false-negative results, Dec. 12
 false-positive results, Dec. 12
 in men, Dec. 27-33
 in men with angina, Dec. 37-41
 in men with angina, effect of tests on outcomes, Dec. 39, 40-41
 in men with angina, negative results, Dec. 39, 40
 in men with angina, positive results, Dec. 38-39, 40
 in men with angina, results that imply diagnostic certainty, Dec. 38
 in men with nonanginal chest pain, Dec. 35-37
 in men with nonanginal chest pain, negative results, Dec. 35-36
 in men with nonanginal chest pain, positive results, Dec. 35
 in men, outcomes, clinical, Dec. 37
 in men, test results, Dec. 37
 with myocardial scintiscan, Dec. 29-30
 performance, effect of history and gender on, Dec. 27-28
 protocol, Dec. 10-12
 stress, in men, interpretation, Dec. 36
 stress, in men, interpretation of, ST-segment depression in, Dec. 37
 stress, with myocardial scintiscan, interpretation, Dec. 35
 stress, test performance in chest pain, Dec. 28
 test performance of, Dec. 31
 in women, Dec. 27-33, 41-44
 in women, with angina, atypical, effect of tests on clinical outcome, Dec. 43
 in women, with angina, atypical, negative results, Dec. 43
 in women, with angina, atypical, positive results, Dec. 42-43
 in women, with angina, typical, Dec. 43-44
 in women, with angina, typical, effect of testing on clinical outcomes, Dec. 44
 in women, with angina, typical, negative results, Dec. 44
 in women, with angina, typical positive results, Dec. 43
 in women, chest pain, nonanginal, Dec. 41-42
 in women, chest pain, nonanginal, negative results, Dec. 42
 in women, chest pain, nonanginal, positive results, Dec. 41-42
 in women, chest pain, nonanginal, test results and clinical outcomes, Dec. 42
 in women, interpretation, Dec. 41-44
 in women, selection, Dec. 41-44
 Electron microscopy: in Alzheimer's disease, Apr. 30-31
 Empyema: subdural, Oct. 48
 Encephalitis: and sleep apnea syndrome, May 44
 Encephalopathy: spongiform, pathogenesis, Aug. 59-61
 Endocarditis, Oct. 42-44
 Endocrine disorders, and sleep apnea syndrome, May 44-47
 dysfunction in anorexia nervosa, June 18-23
 Endophthalmitis, Oct. 51-52
 Enteric diseases: clostridial, Nov. 68-84

Enteritis necroticans, Nov. 69-70
Enterocolitis: necrotizing, in newborn, Nov. 74
Enteropathy: bypass, Nov. 75
Enthesis, Jan. 7
calcification and fusion at, in ankylosing spondylitis, Jan. 9
Enthesopathy, Jan. 7-46
contrasted with rheumatoid arthritis, Jan. 11
Epidural abscess, Oct. 48
Erythrocyte: IgG subclass-erythrocyte complexes forming rosettes with respiratory cells, Feb. 42
Erythromycin: in anaerobic infection, Oct. 32
Escherichia coli: opsonic activity of, Sept. 32
Ethyl alcohol: metabolism of, and cephalosporins, July 16
Exercise
capacity, relationship with ST-segment response, Dec. 30-32
ECG (see *Electrocardiography, exercise*)
myocardial scintigraphy during, thallium 201, Dec. 29
predictors in coronary artery disease, Dec. 47
in spondylitis, ankylosing, Jan. 28-29
ST-segment response to, as predictor of coronary artery disease, Dec. 32
Exercise testing, Dec. 7-71
in chest pain, Dec. 16-44
in coronary artery disease, Dec. 7-71
prediction, Dec. 52-54
pretest risk, estimation of, Dec. 17-23
decision criteria for obtaining, Dec. 32-33
definitions, Dec. 8-10
evaluation of, Dec. 14-16

in men
interpretation of, Dec. 34-41
selection, Dec. 34-41
risk of, Dec. 12-13
sensitivity, Dec. 26-27
specificity, Dec. 26-27
Eyelid infections, Oct. 50

F

Face: in actinomycosis, Nov. 64-65
False-negative rate, Dec. 9
in exercise ECG, Dec. 12
in myocardial scintigraphy, stress thallium 201, Dec. 14
False-positive rate, Dec. 9
in exercise ECG, Dec. 12
in myocardial scintigraphy, stress thallium 201, Dec. 14
Family therapy: in anorexia nervosa, June 33
Fascia: infections of, Nov. 48-50
Fasciitis: clostridial, Nov. 50
Febrile granulocytopenic patient: cephalosporins for, July 49
Fibrosis, cystic, Feb. 34-38
case review, Feb. 45-49
Flora, normal, Oct. 11-16
incidence of various anaerobes as, Oct. 21
Food poisoning: clostridial, Nov. 69
Foot: fetid, of diabetes, Nov. 39-41
Forestier's sign: in ankylosing spondylitis, Jan. 25-26
Fournier's gangrene, Nov. 49-50

G

Gallbladder infections, Nov. 12-14
Gangrene
bacterial synergistic, Nov. 44-45
Fournier's Nov. 49-50
gas, Nov. 50-53
vascular, infected, Nov. 55
Gas
abscess, Nov. 43-44
exchange, during sleep, May 32

-forming soft tissue infection, Nov. 56
gangrene, Nov. 50-53
in wound, evaluation of, Nov. 55-57
Gastric (see Stomach)
Gastrointestinal system: in anorexia nervosa, June 24
Gender
in coronary artery disease, Dec. 20
effect on exercise electrocardiography, Dec. 27-28
Genetics: of HLA-B27, Jan. 7
Genital tract infection, female, Nov. 19-27
anaerobes involved in, Nov. 20
Genitalia
diseases of, Nov. 31-32
external, infections of, Nov. 21-22
Gertsmann-Sträussler syndrome, Aug. 58-59
Gonadal dysfunction: in anorexia nervosa, June 18-21
Granulocytes: polymorphonuclear, interplay with alveolar macrophages, Feb. 60-63
Granulocytopenic patient: febrile, cephalosporins for, July 49
Groin: infections of, Nov. 32
Growth hormone: in anorexia nervosa, June 22-23
Gynecologic infection: postoperative, Nov. 24-25

H

Head: infections of, Oct. 53-57, 60
Heart
in anorexia nervosa, June 23
pacemakers (see Pacemakers)
Hematologic abnormalities: in anorexia nervosa, June 24
Hemorrhage: and hypoprothrombinemia, Nov. 77
Herman's syndrome, Nov. 76-77

Hidradenitis suppurativa, Nov. 36-37
HLA-B27
frequency of, Jan. 15
genetics of, Jan. 7
in spondylitis, seronegative, Jan. 14-15
test, in ankylosing spondylitis, Jan. 22-23
Hormone: growth, in anorexia nervosa, June 22-23
Hospitalization: during Alzheimer's disease, Apr. 62
Host defense
airways and, conducting, Feb. 18-19
of alveolar spaces, Feb. 55-81
deficiency syndromes, adult, Feb. 43-55
evaluation, Feb. 43-55
presentation, clinical, Feb. 43-55
lung, Feb. 11-55
for airway challenges, Feb. 8-9
mechanisms, deficiencies in, and respiratory infections, Feb. 6-98
nose and, Feb. 14-17
oropharynx and, Feb. 14-17
Hyperplasia: lymphonodular, of bowel, with immunoglobulin A deficiency, Nov. 76
Hypogammaglobulinemia
acquired, case review, Feb. 52-55
with meningoencephalitis (see meningoencephalitis, Echovirus, with hypogammaglobulinemia)
Hypoprothrombinemia: with hemorrhage, Nov. 77
Hypothyroidism: and sleep apnea syndrome, May 44-45

I

Ig (see Immunoglobulin)
Ileal bypass: for obesity, Nov. 75

Imaging: liver-spleen, Sept. 29
 Imipenem, July 40-41
 structure, July 41
 Immune opsonins: availability of, Feb. 69-70
 Immunity: cell-mediated, macrophages lacking, Feb. 75-78
 Immunodeficiency: and viruses, Aug. 18
 Immunoglobulin
 A
 deficiency, and bowel hyperplasia, Nov. 76
 secretary, and chronic bronchitis, Feb. 23-28
 G
 dysfunction, Feb. 38-43
 subclass-erythrocyte complexes, forming rosettes with respiratory cells, Feb. 42
 Inclusion cyst: infected, Nov. 36
 Indocyanine green, Sept. 28
 Insight-oriented therapy: in anorexia nervosa, June 32
 Inspiration: negative pressure of, and pharynx, May 13
 Intestine: in anorexia nervosa, June 24
 Intra-abdominal infection (*see* Abdominal infection)
 Intrahepatic shunting: and systemic clearance of bacteria, Sept. 26-28
 Intraperitoneal abscess, Nov. 8-9
 Intrauterine devices: infections associated with, Nov. 24
 Intraventricular conduction abnormalities: chronic, permanent pacing in, Mar. 12-14
 Ischemic score: modified, and dementia, Apr. 47
 J
 Joint infection, Nov. 62-64
 cephalosporins in, July 48-49

K
 Kidney failure: cephalosporins in, dosing interval, July 23
 Kuru, Aug. 48-52
 clinical disease, Aug. 50-51
 diagnosis, Aug. 52
 epidemiology, Aug. 49-50
 laboratory findings, Aug. 51
 pathology, Aug. 51-52
 prognosis, Aug. 65
 treatment, Aug. 65
 Kyphoscoliosis: and sleep apnea syndrome, May 48-49
 L
 Lacrimal apparatus infection, Oct. 51
 Leukoencephalopathy, progressive multifocal, Aug. 39-48
 clinical syndrome, Aug. 41-42
 diagnosis, Aug. 45-46
 epidemiology, Aug. 39-41
 laboratory findings, Aug. 42-43
 pathology, Aug. 43-45
 treatment, Aug. 47-48
 viruses isolated from brain tissue, Aug. 46-47
 Likelihood ratio, Dec. 9
 Liver
 abscess, Nov. 14-15
 disease and bacterial peritonitis, Sept. 11-12
 intrahepatic shunting and systemic clearance of bacteria, Sept. 26-28
 -spleen imaging, Sept. 29
 Lung
 bacteria inhaled into, clearance of, factors responsible for, Feb. 13
 disease, chronic obstructive, May 30-41
 drug therapy, May 40-41
 oxygen therapy, May 39-40
 therapy, May 39
 ventilator therapy, May 39

disease, and sleep apnea
syndrome, May 49-50
host defenses, Feb. 11-55
for airway challenges, Feb.
8-9
infection (see *Pleuropulmonary
infection*)
inflammatory response, and
PMNs, Feb. 78-81
Lymph nodes: suppurative
involvement by anaerobes,
Nov. 33
Lymphonodular hyperplasia: of
bowel with immunoglobulin
A deficiency, Nov. 76

M

Macrophage
alveolar (see *Alveolar,
macrophage*)
intracellular microbes contained
by, Feb. 75
lacking cellular activation and
cell-mediated immunity,
Feb. 75-78
Mastoiditis, Oct. 54
Measles virus: isolated from
subacute sclerosing
panencephalitis, Aug.
28-30
Mediastinitis, Oct. 68
Medication (see *Drugs*)
Meleney's ulcer, Nov. 47
Meningitis, Oct. 48-50
cephalosporins in, July 46-47
Meningoencephalitis, Echovirus,
with
hypogammaglobulinemia,
Aug. 36-39
clinical syndrome, Aug. 36-37
diagnosis, Aug. 38
Echoviruses isolated from
meningoencephalitis, Aug.
38
epidemiology, Aug. 36
laboratory, Aug. 37-38
pathology, Aug. 38
treatment, Aug. 39

Mental status tests: and dementia
syndrome, Apr. 40
Metabolizing drugs, Nov. 77
Methicillin: in anaerobic infection,
Oct. 31
Metronidazole: in anaerobic
infection, Oct. 35
Mezlocillin: in anaerobic infection,
Oct. 31
Microbial flora: of normal airways,
Feb. 19-21
Microscopy: electron, in
Alzheimer's disease, Apr.
30-31
Monitoring: self-monitoring in
bulimia, June 42-43
Monocytes: intracellular microbes
contained by, Feb. 75
Mouth: infections of, Oct. 57-59
Moxalactam: structure, July 14,
17
Multiple sclerosis: possible viral
etiology, Aug. 66-67
Muscle
abscess, Nov. 55
infection of, Nov. 33-57
anaerobic, categories of, Nov.
34
Mutants: viral, temperature-
sensitive, Aug. 17
Myocardium
infarction, acute, permanent
pacing in, Mar. 14-16
infection, Oct. 69
scintigraphy, stress thallium
201, Dec. 13-14
cost, Dec. 14
error in, sources of, Dec. 14
false-negative results, Dec.
14
false-positive results, Dec. 14
protocol, Dec. 13-14
risks, Dec. 14
scintiscan
in coronary artery stenosis,
left main, Dec. 61
with exercise ECG, Dec.
29-30
thallium 201, Dec. 29, 35

M

Myonecrosis
 anaerobic streptococcal, Nov. 53-54
 clostridial, Nov. 50-53
 synergistic nonclostridial, Nov. 54-55

Myotonic dystrophy: and sleep apnea syndrome, May 43

N

Nafcillin: in anaerobic infection, Oct. 31

Neck
 in actinomycosis, Nov. 64-65
 infection, Oct. 53-57, 60

Neckspace infection: deep, Oct. 56-57

Necrosis: of Achilles tendon, Nov. 33

Necrotizing enterocolitis: in newborn, Nov. 74

Neonatal (see Newborn)

Nervous system (see Central nervous system)

Neurofibrillary tangles: in brain, conditions with, Apr. 27

Neurologic diseases
 with possible viral etiology, Aug. 66-68
 sleep apnea syndrome and, May 41-44

Newborn
 enterocolitis, necrotizing, Nov. 74
 infections of, Nov. 89-90

Noma, Nov. 46

Nose: and host defenses, Feb. 14-17

Nutrition
 management in anorexia nervosa, June 29-32
 measurements in anorexia nervosa, June 24-25

Prognostic Nutritional Index, June 28

O

Obesity: ileal bypass for, Nov. 75

Ophthalmic infections, Oct. 49-53

O

Opsonic activity: of *Escherichia coli*, Sept. 32

Opsonins
 immune, availability of, Feb. 69-70
 nonimmune, role of, Feb. 70-73

Oral infections, Oct. 57-59

Orbital cellulitis, Oct. 52-53

Oropharynx: and host defenses, Feb. 14-17

Osteomyelitis
 anaerobes recovered from, types of, Nov. 59
 anaerobic, bones involved in, Nov. 59

Otitis media, Oct. 54

Oxygen
 desaturation, episodic, May 31-34
 desaturation, nocturnal, clinical effects, May 34-37
 cardiovascular, May 35-37
 hematologic, May 37
 neuropsychological, May 34-35
 therapy in COPD, May 39-40

Oxygenation: during sleep, baseline changes, May 30-31

Oxyhemoglobin dissociation curve, May 30

P

Pacemakers, Mar. 6-52
 AAI, Mar. 19-20
 arrhythmia and, Mar. 29-37
 AV intervals and, Mar. 46-47
 classification, international, Mar. 19

DDD, Mar. 40-41
 dual-chamber, arrhythmia initiated by, Mar. 31-33

DVI, Mar. 40
 committed, Mar. 22-23
 noncommitted, Mar. 23-24
 follow-up, Mar. 47-49

- mediated tachycardia,
 - treatment by extension of atrial refractory period, Mar. 35
- output indices, Mar. 43-44
- permanent, choice of, Mar. 38-41
- programmable functions, Mar. 42-47
- rate, Mar. 42-43
- refractory period
 - programmability, Mar. 46
- sensitivity, Mar. 44-46
- single-chamber, Mar. 19-20
- surveillance, Mar. 47-49
- syndrome, and ventriculoatrial conduction, Mar. 27-29
- types, Mar. 18-26
- VVI, Mar. 19-20
 - arrhythmia with, Mar. 30-31
- Wenckebach response to, Mar. 37
- Pacing
 - atrial, Mar. 38-39
 - hemodynamic comparison with ventricular pacing, Mar. 28
 - AV sequential, Mar. 21-24
 - AV universal, Mar. 24-26
 - in bradycardias, indications, Mar. 8-18
 - DDD, Mar. 24-26, 34
 - AV synchrony restoration with, Mar. 29
 - with failure to sense P waves, Mar. 45
 - dual-chamber, Mar. 40-41
 - arrhythmia with, Mar. 31-37
 - arrhythmia sustained by, Mar. 33-36
 - DVI
 - committed, Mar. 23
 - committed, ventricular
 - repetitive response produced by, Mar. 32
 - noncommitted, Mar. 24
 - permanent
 - in AV block, Mar. 8-12
 - in AV block, indications, Mar. 10-12
- in bifascicular block, chronic, indications, Mar. 14
- in intraventricular conduction abnormalities, chronic, Mar. 12-14
- in myocardial infarction, acute, Mar. 14-16
- in sick sinus syndrome and variants, indications, Mar. 18
- in trifascicular block, chronic, indications, Mar. 14
- physiologic
 - special considerations, Mar. 26-37
 - upper rate response, features of, Mar. 36-37
- single-chamber, Mar. 19-20
- ventricular, Mar. 39-40
 - hemodynamic comparison with atrial pacing, Mar. 28
 - synchronized to atrial activity, Mar. 21
- Pain
 - of angina, classification rule for, Dec. 22
 - back
 - in ankylosing spondylitis, five characteristics of, Jan. 21
 - differentiating mechanical back pain from inflammatory pain, Jan. 21
 - chest
 - in coronary artery disease, Dec. 20
 - ECG test performance in, Dec. 28
 - exercise testing in, Dec. 16-44
- Pancreas: infections of, Nov. 15-16
- Panencephalitis
 - rubella, progressive, Aug. 31-36
 - clinical syndrome, Aug. 31-32
 - diagnosis, Aug. 35
 - epidemiology, Aug. 31
 - laboratory findings, Aug. 32-33
 - pathology, Aug. 33-35
 - rubella virus isolates from, Aug. 35-36

Panencephalitis (*cont.*)
 treatment, Aug. 36
 subacute sclerosing, Aug. 22-31
 clinical disease, Aug. 23-25
 diagnosis, Aug. 28
 epidemiology, Aug. 22-23
 laboratory findings, Aug. 25-27
 measles virus isolated from, Aug. 28-30
 pathology, Aug. 27-28
 second virus hypothesis, Aug. 30
 treatment, Aug. 30-31

Paracentesis: abdominal, ascitic fluid during, Sept. 34

Parkinson's disease: possible viral etiology, Aug. 67

Paronychia, Nov. 37

Pelvic inflammatory disease, Nov. 22-23

Penicillin
 β -binding proteins, July 7, 11
 G, in anaerobic infection, Oct. 29
 isoxazolyl, m anaerobic infection, Oct. 31
 structure, July 13
 V, in anaerobic infection, Oct. 29, 31

Pericarditis, Oct. 69

Perineal infection, Nov. 19

Perirectal infection, Nov. 19

Peritoneal abscess, Nov. 8-9

Peritonitis, Nov. 9-10

Peritonitis, bacterial
 definition, Sept. 6-10
 historical perspective, Sept. 6-10
 secondary, Sept. 9-10
 spontaneous, Sept. 6-48
 antibiotics in, Sept. 36-39
 ascites predisposing to infection, characteristics of, Sept. 28-33
 ascitic fluid analysis in, Sept. 14-15, 19-21
 bacterial entrance mode to peritoneal cavity, Sept. 24-26

bacterial source in, Sept. 24-26

case reports, Sept. 40-45

clinical presentation, Sept. 12-14

clinical problems contributing to death, Sept. 21

clinical syndrome, Sept. 10-24

diagnosis, Sept. 33-36

infectious involvement other than ascites and blood, Sept. 15-16

liver disease and, Sept. 11-12

onset relative to time of hospital admission, Sept. 13

organism, Sept. 14-15

pathogenesis, Sept. 24-33

phagocytic activity and, reticuloendothelial system, Sept. 30

predisposing factors, Sept. 16-19

prevention, Sept. 39

prognostic factors, Sept. 23-24

recurrence, Sept. 15-16

survival in, Sept. 21-23

therapy, Sept. 36-39

Peritonillar abscess, Oct. 55-56

Phagocytic activity:
 reticuloendothelial system, and bacterial peritonitis, Sept. 30

Pharmacotherapy
 in anorexia nervosa, June 32
 in bulimia, June 43-44

Pharynx
 collapse, beneficial effect of applied positive pressure to, May 22
 CT of, May 12
 negative pressure of normal inspiration and, May 13

Pickwickian syndrome:
 relationship with sleep apnea syndrome, May 23-24

Pilonidal sinus: infected, Nov. 46-47

"Pink puffers:" vs. "blue bloaters," May 37-41

Piperacillin
 in anaerobic infection, Oct. 31
 structure, July 15
Pleuropulmonary infection, Oct. 59-68
 anaerobes encountered in, major, Oct. 63
 clinical picture, Oct. 64-65
 diagnosis, Oct. 65-66
 etiologic agents, Oct. 63-64
 history, Oct. 60-61
 pathogenesis, Oct. 61-62
 therapy, Oct. 66-68
PMNs: and lung inflammatory response, Feb. 78-81
Pneumatosis cystoides intestinalis, Nov. 75
Pneumonia
 alveolar macrophage defects contributing to, Feb. 66-78
 cephalosporins for, July 44-46
Poisoning: clostridial food, Nov. 69
Poliomyelitis: and sleep apnea syndrome, May 42-43
Polyarthropathy: juvenile chronic, Jan. 42-43
Polymorphonuclear granulocytes: interplay with alveolar macrophages, Feb. 60-63
Polysomnography: in sleep apnea syndrome, May 8-9
Porins, July 7, 11
Postpartum infections, Nov. 26-27
Prevalence, Dec. 8
 relationship with probability, Dec. 10
Probability, Dec. 8
 posttest, Dec. 8
 pretest, Dec. 8
 relationship with prevalence, Dec. 10
Prognostic Nutritional Index, June 28
Prostate: cultures, Nov. 30
Protein
 binding and cephalosporins, July 23-24
 concentration in ascitic fluid in peritonitis, Sept. 18
 penicillin-binding, July 7, 11
Pseudomonas, cephalosporin activity against, July 35-38
 clinical correlates, July 35-38
Psoriatic arthritis, Jan. 39-42
 eight types, Jan. 39
Psychotherapy
 in anorexia nervosa, June 32-33
 in bulimia, June 42-43
Psychotropic drugs: in Alzheimer's disease, Apr. 57-60
Pulmonary (see *Pleuropulmonary infection*)
Pus: from subacromial bursa, Nov. 33
P waves: DDD pacing with failure to sense, Mar. 45
Pyoderma, Nov. 37
Pyogenic infections: pathogenesis, Oct. 17-22
Pyometra, Nov. 24

R

Radiography: in ankylosing spondylitis, Jan. 23
Rectum: infections of, Nov. 19
Reiter's syndrome, Jan. 32-39
Respiratory
 cells forming rosettes with IgG subclass-erythrocyte complexes, Feb. 42
 infections, and host defense mechanism deficiencies, Feb. 6-9
 tract mucosa, bacterial adherence to, and colonization, Feb. 21-23
Reticuloendothelial system
 phagocytic activity: and bacterial peritonitis, Sept. 30
Retropitoneal abscess, Nov. 18-19
Rheumatoid arthritis: contrasted with enthesopathies, Jan. 11
Rieter's syndrome
 diagnosis, Jan. 34-35
 history, clinical, Jan. 35-36

Rieter's syndrome (*cont.*)
management, Jan. 37-39
Rubella (*see* Panencephalitis,
rubella)

S

Sacroiliitis, Jan. 24
grade IV with fusion, Jan. 25
Scanning: liver-spleen, Sept. 29
Schober test: in ankylosing
spondylitis, Jan. 23-24
Scintigraphy (*see* Myocardium,
scintigraphy)
Scintiscan (*see* Myocardium,
scintiscan)
Sclerosing (*see* Panencephalitis,
subacute sclerosing)
Sclerosis
amyotrophic lateral, possible
viral etiology, Aug. 67-68
multiple, possible viral etiology,
Aug. 66-67
Scrotum: infections of, Nov. 32
Sebaceous cyst: infected, Nov. 36
Septic abortion, Nov. 25-26
Shunting: intrahepatic, and
systemic clearance of
bacteria, Sept. 26-28
Sick sinus syndrome and variants,
Mar. 16-18
permanent pacing in,
indications, Mar. 18
Sinus
pilonidal, infected, Nov.
46-47
visceral sinus tract, infected,
Nov. 45-46
Sinusitis, Oct. 54-55
Skin
abscess, Nov. 37-39
anaerobes in, incidence of,
Nov. 38
infection of, Nov. 33-57
anaerobic, categories of, Nov.
34
cephalosporins in, July 48
ulcer, infected, Nov. 35-36

Sleep
apnea syndrome, May 6-24
acromegaly and, May 45-46
androgen excess and, May
46-47
appliances in, May 21
autonomic dysfunction and,
May 42
hypothyroidism and, May
44-45
kyphoscoliosis and, May
48-49
lung disease and, May 49-50
myotonic dystrophy and, May
43
neurologic diseases and, May
41-44
pathogenesis, May 10-11
pathophysiology, May 11-17
pharyngeal airway in, May 11
poliomyelitis and, May 42-43
polysomnography in, May 8-9
relationship with Pickwickian
syndrome, May 23-24
spine injury and, cervical,
May 43
stroke and, May 44
sudden infant death syndrome
and, May 50-52
surgery of, May 21-23
treatment, May 17-23
weight loss and, May 18-19
in asymptomatic subjects, May
25-30
epidemiology, May 25-27
gas exchange during, May 32
Snoring, May 28-29
as risk factor, May 29-30
Soft tissue infection
cephalosporins in, July 48
gas-forming, Nov. 56
synergistic, Nov. 27

Spine
 "bamboo," in spondylitis, Jan. 14
 cervical, injury, and sleep apnea syndrome, May 43

Spleen
 infections of, Nov. 16
 -liver imaging, Sept. 29

Spondylarthritis: seronegative, Jan. 10-17

Spondylitis
 advanced, Jan. 14
 ankylosing (*see below*)
 lordosis in, normal lumbar, "straightening" of, Jan. 13
 "squaring" of vertebral bodies in, Jan. 13

Spondylitis, ankylosing, Jan. 17-32
 back pain in, five characteristics of, Jan. 21
 calcification at enthesis in, Jan. 9
 chest expansion in, Jan. 24-25
 diagnosis, Jan. 20-26
 exercise in, Jan. 28-29
 Forestier's sign in, Jan. 25-26
 fusion at enthesis in, Jan. 9
 history, clinical, Jan. 18-20
 HLA-B27 test in, Jan. 22-23
 management, Jan. 27-32
 medical, Jan. 30-32
 New York criteria for, Jan. 20
 prevalence, Jan. 26-27
 radiography of, Jan. 23
 Schober test in, Jan. 23-24
 signs, special clinical, Jan. 23-26
 straight lower back in, Jan. 19
 supportive therapy of, Jan. 29-30

Stenosis (*see* Coronary artery stenosis)

Stomach
 in anorexia nervosa, June 24
 bypass, illustration, May 19
 infections related to, Nov. 16
 partition, illustration, May 19

Streptococcal myonecrosis:
 anaerobic, Nov. 53-54

Stroke
 dementia due to, Apr. 43-47
 in sleep apnea syndrome, May 44

ST-segment depression: in exercise stress ECG in men, Dec. 37

ST-segment response
 to exercise as predictor of coronary artery disease, Dec. 32
 relationship with exercise capacity, Dec. 30-32

Subcutaneous abscess, Nov. 37-39
 anaerobes in, incidence of, Nov. 38

Subcutaneous tissue infection, Nov. 33-57
 anaerobic, categories of, Nov. 34

Subdural empyema, Oct. 48

Subphrenic abscess, Nov. 8-9

Sudden infant death syndrome:
 and sleep apnea, May 50-52

Sulfur colloid, Sept. 28

Surgical prophylaxis:
 cephalosporins for, July 49-50

Susceptibility testing: and anaerobic infection, Oct. 28

T

Tachycardia: pacemaker-mediated, treatment by extension of atrial refractory period, Mar. 35

Taxonomy, Oct. 10-11

Technetium-99m sulfur colloid: for liver-spleen imaging, Sept. 29

Tendon: Achilles, necrosis of, Nov. 33

Test
 sensitivity, Dec. 8
 specificity, Dec. 8

Tetanus, Nov. 82-88
 clinical picture, Nov. 84-85

Tetanus (*cont.*)
 diagnosis, Nov. 85-86
 epidemiology, Nov. 83
 pathogenesis, Nov. 83-84
 prognosis, Nov. 87-88
 prophylaxis, Nov. 88
 guide to, Nov. 88
 therapy, Nov. 86-87

Tetracycline: in anaerobic infection, Oct. 32, 34

Thallium 201
 myocardial scintiscan, Dec. 29
 test performance during exercise, Dec. 29, 35

scintigraphy (*see* Myocardium, scintigraphy, stress thallium 201)

Thyroid: in anorexia nervosa, June 21

Ticarcillin: in anaerobic infection, Oct. 31

Tomography: computed, of pharynx, May 12

Tonsil: peritonsillar abscess, Oct. 55-56

Toxic drug reactions
 to cephalosporins, July 51-52
 dementia syndrome due to, Apr. 52-53

Toxicity: of drugs active against anaerobic bacteria, Oct. 33

Trifascicular block: chronic, permanent pacing in, indications, Mar. 14

Tropical ulcer, Nov. 37

U

Ulcer
 decubitus, infected, Nov. 41-42
 Meleney's, Nov. 47
 skin, infected, Nov. 35-36
 tropical, Nov. 37

Urinary tract
 bacteremia related to, Nov. 30-31
 infection, Nov. 27-31
 anaerobes in voided urine, Nov. 28-30

cephalosporins in, July 46
 pathogenesis, Nov. 27-28

V

Vaginosis: anaerobic, Nov. 20-21

Vasopressin: in anorexia nervosa, June 23

Ventilators: in COPD, May 39

Ventricle
 intraventricular conduction abnormalities, chronic, permanent pacing in, Mar. 12-14

pacing, Mar. 39-40
 hemodynamic comparison with atrial pacing, Mar. 28
 synchronized to atrial activity, Mar. 21

repetitive response produced by committed DVI pacing, Mar. 32

Ventriculoatrial conduction: and pacemaker syndrome, Mar. 27-29

Vertebra: bodies, "squaring" in spondylitis, Jan. 13

Vessels
 in anorexia nervosa, June 23
 gangrene of, infected, Nov. 55

Vincent's angina, Oct. 55-56

Viruses
 antigens, changes in, Aug. 15-16
 conventional, properties of, Aug. 18-21
 defective interfering particles, Aug. 16-17

Echovirus (*see* Meningoencephalitis, Echovirus)
 in etiology of neurologic diseases, possible etiology, Aug. 66-68

failure
 to express viral antigens on cell membranes, Aug. 16
 to release viral particles, Aug. 16

immunodeficiency and, Aug. 18
infection (*see below*)
measles, isolated from subacute
sclerosing panencephalitis,
Aug. 28-30
mutants, temperature-sensitive,
Aug. 17
rubella, isolates from
progressive rubella
panencephalitis, Aug. 35-36
unconventional
microbiology of, Aug. 61-64
properties of Aug. 18-21
Virus infection
acute, Aug. 7-15
pathogenesis within nervous
system, Aug. 13-14
cell-associated, Aug. 16-17
of central nervous system
invasion of central nervous
system, Aug. 10-13
pathogenesis, Aug. 7-18
slow virus diseases, Aug.
21-66

termination of, Aug. 14-15
transmission routes, Aug.
8-10
chronic
pathogenesis, Aug. 15-18
role of antibody in, Aug.
17-18
conventional, clinical syndromes
associated with, Aug. 22-48
unconventional, diseases
associated with, Aug.
48-59
Visceral sinus tract: infected, Nov.
45-46

W

Weight
gain after therapy in anorexia
nervosa, June 34
loss, and sleep apnea syndrome,
May 18-19
Wenckebach response: to
pacemaker, Mar. 37